Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Panaxia's topical cannabis extract is a pharmaceutical-grade formulation designed for the treatment of psoriasis. It functions by modulating the endocannabinoid system through the activation of Cannabinoid receptor 1 (CB1) and Cannabinoid receptor 2 (CB2). This modulation aims to reduce the chronic inflammation and skin symptoms associated with psoriasis. Developed by Panaxia Pharmaceutical Industries, this product is part of their pipeline of medical cannabis delivery systems.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabis topical (Panaxia).